source
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…